Tenax Therapeutics (Nasdaq: TENX) presented additional results from its Phase 3 LEVEL clinical trial of TNX-103 (oral levosimendan) at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE